Repeat infusion of chimeric antigen receptor (CAR) T-cell is effective for patients with refractory or relapsed multiple myeloma (RRMM) after failing a prior CAR Tcell therapy. It is unknown whether B-cell maturation antigen (BCMA) CAR T-cell is effective for patients with RRMM after anti-G protein-coupled receptor, cl...
Xiao-Tian Zhang, Fan Xia, Kun-Ming Qi et al.· Haematologica· 0 citations
ABSTRACT Chimeric antigen receptor (CAR)‐T cell therapy for solid tumors is limited by antigen heterogeneity and T cell exhaustion. To address these limitations, we develop a novel multi‐targeting “Bicephali” CAR‐T platform featuring a dual‐transmembrane protein with two distinct extracellular antigen‐binding domains a...
Li-Na Wang, Yan-Lei Zhang, S. Peng et al.· Advancement of science· 0 citations
Recent advances, persistent challenges, and emerging strategies for CAR-T cell therapy in pediatric solid tumors are summarized and rational combination strategies involving CAR-T cell therapy with chemotherapy, radiotherapy, and immune checkpoint inhibitors aimed at improving therapeutic efficacy and safety are discus...
Yu-Miao Mai, Zi-Wen Wang, Juan Wang et al.· Experimental Hematology & On...· 0 citations
The initial results indicate that CD7 CAR-T cell therapy exhibits a manageable safety profile and preliminary efficacy in R/R AML patients, supporting further investigation in larger trials.
Mingming Zhang, Lianxuan Liu, Shan Fu et al.· Leukemia· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.
